TolerogenixX Publishes Three-Year Follow-Up Data from Phase I Trial of Immune Tolerance-Inducing MIC-Lx Cell Therapy
September 26, 2022 04:00 ET
|
AKAMPION
Publication in high-impact Journal of the American Society of NephrologyResults pave the way for a novel cell therapy in organ transplantation Heidelberg, September 26, 2022 – TolerogenixX...
InfanDx AG ernennt Nicole Witzmann zum Finanzvorstand
September 01, 2022 05:00 ET
|
AKAMPION
- Corporate Finance Expertin mit mehr als acht Jahren Erfahrung im Gesundheitssektor Köln/Berlin, Deutschland, und Boston, USA, 01. September 2022 - Die InfanDx AG, ein privates...
InfanDx AG Appoints Nicole Witzmann as Chief Financial Officer
September 01, 2022 05:00 ET
|
AKAMPION
Seasoned professional with more than 8 years of healthcare corporate finance experience Cologne/Berlin, Germany, and Boston, MA, USA, September 01, 2022 – InfanDx AG, a privately held...
BellaSeno Starts Two Clinical Trials of its Resorbable Breast and Chest Implants
August 04, 2022 04:00 ET
|
AKAMPION
Resorbable implants to treat pectus excavatum and silicone breast implant revision / congenital defect correctionFirst patients treated in Australia Leipzig, Germany, August 4, 2022 – BellaSeno...
ELITechGroup und InfanDx AG kooperieren bei der Entwicklung und Herstellung des HypoxE® Neonatal-Tests für klinische Labore
July 27, 2022 04:00 ET
|
AKAMPION
HypoxE® Test ermöglicht die Früherkennung von hypoxisch-ischemischer Enzephalopathie (HIE), bedingt durch Sauerstoffmangel bei der GeburtELITechGroup übernimmt Auftragsentwicklung und -herstellung von...
ELITechGroup and InfanDx AG to Collaborate on the Development and Manufacturing of HypoxE® Neonatal Care Test for Clinical Laboratories
July 27, 2022 04:00 ET
|
AKAMPION
HypoxE® Test allows for the early detection of Hypoxic-Ischemic Encephalopathy (HIE) caused by lack of oxygen during birthELITechGroup to provide contract development and manufacturing services for...
ImmunOs Therapeutics lève 74 millions de dollars lors d’un tour de table de série B
June 07, 2022 01:30 ET
|
AKAMPION
- L’entrée au capital de Samsara, Lightspeed, Gimv et Mission BioCapital renforce le panel d'investisseurs de la société et lui permet d’asseoir sa présence outre-Atlantique - La société crée une...
ImmunOs Therapeutics schließt Serie B Finanzierung in Höhe von US $74 Millionen ab
June 07, 2022 01:30 ET
|
AKAMPION
- Samsara, Lightspeed, Gimv und Mission BioCapital stärken als neue Anteilseigner das Investorenkonsortium und erweitern die transatlantische Präsenz - Unternehmen gründet US-Niederlassung zum...
ImmunOs Therapeutics Raises $74 Million Series B Financing Round
June 07, 2022 01:30 ET
|
AKAMPION
- New investors Samsara, Lightspeed, Gimv, and Mission BioCapital further strengthen investor base and expand transatlantic footprint - Company establishes U.S. subsidiary to accelerate...
Dopavision Appoints Mark S. Wuttke, Ph.D., as Chief Executive Officer
May 25, 2022 04:05 ET
|
AKAMPION
- Former Novartis ophthalmology program head significantly strengthens Dopavision´s management capabilities- Company recently initiated clinical trial of novel digital therapeutic for childhood myopia...